Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | ALKBH1 | Q13686 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328539 | 0.85 | PTGER4 (0.49) | PTGER4NPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL9356623 | 0.84 | RAB9A (0.52) | MRGPRX4ALKBH1PTGER4NPC1CYP1A2 | |
| SCHEMBL10328594 | 0.83 | MEN1 (0.50) | PTGER4NPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL13323405 | 0.83 | MRGPRX4 (0.48) | MRGPRX4PTGER4NPC1CYP1A2CYP2C19 | |
| SCHEMBL1037140 | 0.82 | PTGER4 (0.52) | PTGER4NPC1CYP1A2CYP2C19RECQL | |
| SCHEMBL10328616 | 0.81 | RXRA (0.52) | MRGPRX4PTGER4NPC1CYP1A2CYP2C19 | |
| SCHEMBL10328650 | 0.81 | RAB9A (0.50) | MRGPRX4PTGER4NPC1CYP1A2CYP2C19 | |
| SCHEMBL10328621 | 0.81 | NPC1 (0.53) | MRGPRX4PTGER4NPC1CYP1A2CYP2C19 | |
| SCHEMBL10328542 | 0.81 | MRGPRX4 (0.50) | MRGPRX4PTGER4NPC1CYP1A2CYP2C19 | |
| SCHEMBL3334602 | 0.81 | NPC1 (0.67) | MRGPRX4PTGER4NPC1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| EP-2120923-B1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI SA (FR) | 2012-07-18 | — | — | EP | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008086949-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | PC, PCK1, PDK4 | MRGPRX4 2140/4885ALKBH1 4115/4885PTGER4 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.